Profile data is unavailable for this security.
About the company
Revelation Biosciences, Inc. is a clinical-stage life sciences company engaged in the development of innate immune system therapeutics and diagnostics. Its therapeutic candidates are based on its Gemini formulation of active ingredient phosphorylated hexaacyl disaccharide (PHAD), a synthetic version of monophosphoryl lipid A (MPLA) that is known to stimulate Toll-like receptor 4 (TLR-4). Its product candidates include Gemini-SSI, which is being developed for the prevention and treatment of surgical sit infection; Gemini-AKI, which is being developed as a potential therapy for the prevention and treatment of acute kidney injury as a result of cardiac surgery; and Gemini-CKD, which is being developed as a potential therapy for the prevention and treatment of chronic kidney disease. Stimulation of TLR4 via Gemini leads to a controlled production of varied cytokines and chemokines which modulate the activity of the innate and adaptive immune response, relative to Lipopolysaccharides (LPS).
- Revenue in USD (TTM)0.00
- Net income in USD-15.90m
- Incorporated2019
- Employees9.00
- LocationRevelation Biosciences Inc4660 Lajolla Village Drive, Suite 100SAN DIEGO 92122United StatesUSA
- Phone+1 (650) 800-3717
- Fax+1 (302) 645-1280
- Websitehttps://www.revbiosciences.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
InMed Pharmaceuticals Inc | 4.60m | -7.68m | 2.78m | 13.00 | -- | 0.202 | -- | 0.605 | -1.33 | -1.33 | 0.6027 | 1.03 | 0.3546 | 2.44 | 14.99 | -- | -59.20 | -92.09 | -69.92 | -113.17 | 23.94 | -- | -166.94 | -543.29 | 3.78 | -- | 0.00 | -- | 11.18 | -- | 3.42 | -- | -19.10 | -- |
Halberd Corp | 281.24k | 25.34k | 2.80m | 3.00 | 1.90 | -- | 110.28 | 9.95 | 0.0023 | 0.0023 | 0.0018 | -0.0002 | 0.1449 | 0.0303 | 2.52 | -- | 1.31 | -- | 4.58 | -- | 50.00 | -- | 9.01 | -- | 0.2661 | 1.35 | 1.02 | -- | 271.52 | -- | -60.11 | -- | -- | -- |
Avenue Therapeutics Inc | 0.00 | -5.87m | 2.82m | 3.00 | -- | 0.492 | -- | -- | -3.02 | -3.02 | 0.00 | 4.00 | 0.00 | -- | -- | 0.00 | -177.94 | -186.91 | -- | -287.70 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -192.15 | -- | -- | -- |
Bio Path Holdings Inc | 0.00 | -11.60m | 3.04m | 10.00 | -- | 2.10 | -- | -- | -17.91 | -17.91 | 0.00 | 0.5655 | 0.00 | -- | -- | 0.00 | -199.23 | -70.80 | -321.87 | -76.87 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -15.94 | -- | -- | -- |
Revelation Biosciences Inc | 0.00 | -15.90m | 3.04m | 9.00 | -- | 1.17 | -- | -- | -29.75 | -29.75 | 0.00 | 0.6939 | 0.00 | -- | -- | 0.00 | -112.35 | -- | -253.32 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 98.89 | -- | -- | -- |
Oragenics Inc | 7.47k | -19.52m | 3.12m | 5.00 | -- | -- | -- | 417.30 | -6.99 | -6.99 | 0.0023 | 0.2377 | 0.0013 | -- | -- | 1,494.00 | -349.31 | -97.60 | -451.26 | -106.24 | -- | -- | -261,261.60 | -36,169.75 | -- | -- | 0.00 | -- | -71.37 | -- | -44.56 | -- | 51.64 | -- |
Talis Biomedical Corp | 408.00k | -51.03m | 3.13m | 99.00 | -- | 0.0645 | -- | 7.68 | -28.02 | -28.02 | 0.224 | 26.69 | 0.0042 | -- | 1.53 | 4,121.21 | -52.13 | -68.18 | -57.23 | -74.22 | 95.10 | -- | -12,506.37 | -1,615.96 | -- | -- | 0.00 | -- | -55.65 | -2.24 | 45.13 | -- | -1.83 | -- |
Therapeutic Solutions International Inc | 91.38k | -2.00m | 3.17m | 3.00 | -- | 2.30 | -- | 34.74 | -0.0005 | -0.0005 | 0.00002 | 0.0003 | 0.0252 | 1.29 | 5.24 | 30,460.00 | -63.67 | -162.32 | -153.29 | -- | 65.18 | 67.79 | -2,530.31 | -2,391.85 | 0.3883 | -6.94 | 0.3164 | -- | -52.13 | 95.35 | 43.11 | -- | -- | -- |
Petros Pharmaceuticals Inc | 4.12m | -20.64m | 3.19m | 21.00 | -- | 0.3825 | -- | 0.774 | -6.54 | -6.54 | 1.00 | 0.988 | 0.1529 | 0.6795 | 1.89 | 196,223.30 | -26.18 | -32.43 | -39.25 | -68.05 | 70.21 | 62.04 | -171.23 | -201.70 | 1.26 | -- | 0.4539 | -- | -2.83 | -16.15 | 31.06 | -- | -- | -- |
Biostax Corp | 0.00 | -1.51m | 3.27m | -- | -- | -- | -- | -- | -0.0181 | -0.0181 | 0.00 | -0.0633 | 0.00 | -- | -- | -- | -395.44 | -81.51 | -- | -- | -- | -- | -- | -- | -- | -4.04 | -- | -- | -- | -- | 53.32 | -- | -- | -- |
Lipella Pharmaceuticals Inc | 507.20k | -4.14m | 3.27m | 5.00 | -- | 1.82 | -- | 6.45 | -0.6188 | -0.6188 | 0.074 | 0.224 | 0.1788 | -- | 16.01 | 101,440.00 | -146.02 | -- | -169.27 | -- | -- | -- | -816.72 | -- | -- | -- | 0.00 | -- | 144.15 | -- | -77.81 | -- | -- | -- |
NovaBay Pharmaceuticals Inc | 12.02m | -15.98m | 3.34m | 24.00 | -- | -- | -- | 0.2778 | -65.73 | -65.91 | 21.94 | -0.4577 | 1.21 | 2.29 | 7.59 | 500,958.30 | -105.75 | -61.51 | -205.52 | -83.89 | 58.55 | 59.99 | -87.67 | -86.47 | 0.4302 | -- | 8.81 | -- | 2.24 | 3.32 | -2.66 | -- | -15.46 | -- |
Holder | Shares | % Held |
---|---|---|
UBS Securities LLCas of 31 Mar 2024 | 4.18k | 0.26% |
Tower Research Capital LLCas of 31 Mar 2024 | 3.12k | 0.19% |
Securities America Advisors, Inc.as of 31 Mar 2024 | 300.00 | 0.02% |
RBC Dominion Securities, Inc.as of 31 Mar 2024 | 36.00 | 0.00% |
Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Mar 2024 | 5.00 | 0.00% |
Wells Fargo Bank, NA (Private Banking)as of 31 Mar 2024 | 3.00 | 0.00% |
POM Investment Strategies LLCas of 30 Jun 2024 | 1.00 | 0.00% |
AXA Investment Managers UK Ltd.as of 31 Mar 2024 | 0.00 | 0.00% |
Walleye Capital LLCas of 31 Mar 2024 | 0.00 | 0.00% |
Sabby Management LLCas of 31 Mar 2024 | 0.00 | 0.00% |